Print Page     Close Window     

SEC Filings

8-K
BEIGENE, LTD. filed this Form 8-K on 01/07/2019
Entire Document
 

 

Treatment - Naïve (n=80) Relapsed/Refractory (n=536) Total (n=616) Median Follow - Up 14.5 months Total Treatment D/C 19 (24%) 231 (43%) 250 (41%) Toxicity/Tolerability 12 (15%) 117 (22%) 129 (21%) CLL/SLL Progression 3 (4%) 49 (9%) 52 (8%) Transformation (RT or HD) 0 (0%) 10 (2%) 10 (2%) Death Unrelated to Treatment 1 (1%) 28 (5%) 29 (5%) Physician or Patient Decision 2 (2%) 15 (3%) 17 (3%) Transplant 0 (0%) 8 (1.5%) 8 (1%) Financial Concerns 0 (0%) 1 (0.2%) 1 (0.2%) Secondary Malignancy 1 (1%) 2 (0.5%) 3 (0.5%) 29 Ibrutinib Discontinuation for Toxicity or Progression in CLL/SLL Source: Mato ASH 2016 Note: at med follow - up 24.5 mos , 22% discontinuation rate with acalabrutinib in R/R CLL; 9% AE - related, 8% PD - related. Byrd ASH 2017.

 


© 2016 BeiGene. All Rights Reserved.